Considering the median age of CLL patients at treatment requirement, the impact of comorbidities, and the toxicity associated to regimens that combine BTK inhibitors and anti-BCL2 drugs, this issue is of daily relevance in clinical practice [4]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.